Pfizer Adds to Data on Novel RA Drug

Xconomy New York — 

Pfizer (NYSE: PFE) announced in a press release that tofacitinib, its experimental JAK inhibitor for rheumatoid arthritis (RA), performed well in the final two pivotal phase 3 trials. Patients taking both the 5 and 10 milligram doses showed statistically significant changes versus placebo in reducing the symptoms of RA. The announcement comes two weeks after the New York-based pharmaceutical giant said that in a separate trial, the 10 milligram dose of tofacitinib performed better than the smaller dose. The company plans to release a more detailed analysis at an upcoming medical meeting.